These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Uptake and effect of praziquantel and the major human oxidative metabolite, 4-hydroxypraziquantel, by Schistosoma japonicum. Xiao SH, You JQ, Guo HF, Catto BA. J Parasitol; 1991 Apr; 77(2):241-5. PubMed ID: 1901360 [Abstract] [Full Text] [Related]
4. Improvement of ultrasonographic and serologic changes in Schistosoma japonicum-infected patients after treatment with praziquantel. Ohmae H, Tanaka M, Hayashi M, Matsuzaki Y, Kurosaki Y, Blas BL, Portillo GG, Sy OS, Irie Y, Yasuraoka K. Am J Trop Med Hyg; 1992 Jan; 46(1):99-104. PubMed ID: 1536391 [Abstract] [Full Text] [Related]
7. [Schistosomiasis japonica of the liver]. Kawashima T, Sekiya C. Ryoikibetsu Shokogun Shirizu; 1995 Jan; (7):97-9. PubMed ID: 8749426 [No Abstract] [Full Text] [Related]
8. Plasma pharmacokinetics and therapeutic efficacy of praziquantel and 4-hydroxypraziquantel in Schistosoma japonicum-infected rabbits after oral, rectal, and intramuscular administration. Xiao SH, You JQ, Guo HF. Am J Trop Med Hyg; 1992 May; 46(5):582-8. PubMed ID: 1599052 [Abstract] [Full Text] [Related]
9. Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice. Ma Z, Liu X, Dong H, Xia D, Wang L, Chen Y, Xiong Y. Parasitol Res; 2018 Sep; 117(9):2831-2839. PubMed ID: 29946766 [Abstract] [Full Text] [Related]
12. [Expression of Toll-like receptors 2 and 6 in mice liver during Schistosoma japonicum infection]. Tang JJ, Ji XF, Zhu XM, Huang HY, Li Z. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2014 Apr; 32(2):101-5. PubMed ID: 25065207 [Abstract] [Full Text] [Related]
13. [Pigment deposit in liver of BALB/c mice infected by Schistosoma japonicum and its relation to the effect of praziquantel treatment]. Tao J, Cai WM, Zhang BB, Huang Y, Xiang Q, Liu RH. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2006 Feb 28; 24(1):79-80. PubMed ID: 16866157 [Abstract] [Full Text] [Related]
15. Reduced levels of mutagen processing potential in the Schistosoma japonicum-infected mouse liver. Matsuoka H, Aji T, Ishii A, Arimoto S, Wataya Y, Hayatsu H. Mutat Res; 1989 Nov 28; 227(3):153-7. PubMed ID: 2509904 [Abstract] [Full Text] [Related]
16. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Sotelo J, Jung H. Clin Pharmacokinet; 1998 Jun 28; 34(6):503-15. PubMed ID: 9646011 [Abstract] [Full Text] [Related]
18. Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW. Trans R Soc Trop Med Hyg; 1990 Jun 28; 84(3):389-93. PubMed ID: 2124391 [Abstract] [Full Text] [Related]
19. Determination of the period for establishment of a liver network echogenic pattern in Schistosoma japonicum infection. Chigusa Y, Otake H, Ohmae H, Kirinoki M, Ilagan EJ, Barzaga NG, Kawabata M, Hayashi M, Matsuda H. Parasitol Int; 2006 Mar 28; 55(1):33-7. PubMed ID: 16216544 [Abstract] [Full Text] [Related]
20. The combined treatment of praziquantel with osteopontin immunoneutralization reduces liver damage in Schistosoma japonicum-infected mice. Chen BL, Zhang GY, Wang SP, Li Q, Xu MH, Shen YM, Yan L, Gu H, Li J, Huang YL, Mu YB. Parasitology; 2012 Apr 28; 139(4):522-9. PubMed ID: 22309838 [Abstract] [Full Text] [Related] Page: [Next] [New Search]